|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Division of Transplantation Immunology, Department of Pathology and Laboratory Medicine, Biesecker Pediatric Liver Center, Childrens Hospital of Philadelphia, and University of Pennsylvania School of Medicine, Philadelphia, PA 19104;
Department of Medical Chemistry and Molecular Biology, Graduate School of Medicine, Kyoto University, Yoshida, Kyoto, Japan; and
Department of Pathology and Immunology, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110
Although fully MHC-mismatched murine cardiac allografts are rapidly rejected, allografts mismatched at only MHC class I or class II alleles survive long term; the immunologic basis for the long-term survival of MHC class I- or II-mismatched allografts is unknown. We examined the roles of two recently described inhibitory receptors, B and T lymphocyte attenuator (BTLA) and programmed death-1 (PD-1), in the survival of partially or fully MHC-mismatched allografts using gene-deficient recipients as well as through use of blocking mAbs in wild-type hosts. Partially MHC-mismatched allografts showed strong induction of BTLA, but not PD-1 mRNA and survived long term in wild-type recipients, whereas targeting of BTLA or its ligand, herpesvirus entry mediator, but not PD-1, prompted their rapid rejection. By contrast, fully MHC-mismatched cardiac allografts were acutely rejected in wild-type recipients despite the induction of both BTLA and PD-1. Targeting of PD-1 in several fully MHC-mismatched models accelerated rejection, whereas targeting of BTLA unexpectedly enhanced PD-1 induction by alloreactive CD4 and CD8 T cells and prolonged allograft survival. In vitro studies using allogeneic dendritic cells and T cells showed that at low levels of T cell activation, BTLA expression was primarily induced, but that with increasing degrees of T cell activation, the expression of PD-1 was strongly up-regulated. These data suggest that BTLA and PD-1 exert distinct inhibitory actions in vivo, with the BTLA/herpesvirus entry mediator pathway appearing to dominate in regulating responses against a restricted degree of allogeneic mismatch.
This article has been cited by other articles:
![]() |
H. M'Hidi, M.-L. Thibult, B. Chetaille, F. Rey, R. Bouadallah, R. Nicollas, D. Olive, and L. Xerri High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia Am J Clin Pathol, October 1, 2009; 132(4): 589 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, N. K. Brown, M. J. Ruddy, M. L. Miller, Y. Lee, Y. Wang, K. M. Murphy, K. Pfeffer, L. Chen, J. Kaye, et al. B and T Lymphocyte Attenuator Tempers Early Infection Immunity J. Immunol., August 1, 2009; 183(3): 1946 - 1951. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Crawford and E. J. Wherry Editorial: Therapeutic potential of targeting BTLA J. Leukoc. Biol., July 1, 2009; 86(1): 5 - 8. [Full Text] [PDF] |
||||
![]() |
W. Truong, W. W. Hancock, J. C. Plester, S. Merani, D. C. Rayner, G. Thangavelu, K. M. Murphy, C. C. Anderson, and A. M. J. Shapiro BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice J. Leukoc. Biol., July 1, 2009; 86(1): 41 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Miller, Y. Sun, and Y.-X. Fu Cutting Edge: B and T Lymphocyte Attenuator Signaling on NKT Cells Inhibits Cytokine Release and Tissue Injury in Early Immune Responses J. Immunol., July 1, 2009; 183(1): 32 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, M. Alexiou, N. Martin-Orozco, Y. Chung, R. I. Nurieva, L. Ma, Q. Tian, G. Kollias, S. Lu, D. Graf, et al. Cutting Edge: A Critical Role of B and T Lymphocyte Attenuator in Peripheral T Cell Tolerance Induction J. Immunol., April 15, 2009; 182(8): 4516 - 4520. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Vendel, J. Calemine-Fenaux, A. Izrael-Tomasevic, V. Chauhan, D. Arnott, and D. L. Eaton B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK J. Immunol., February 1, 2009; 182(3): 1509 - 1517. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Koehn, M. L. Ford, I. R. Ferrer, K. Borom, S. Gangappa, A. D. Kirk, and C. P. Larsen PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue J. Immunol., October 15, 2008; 181(8): 5313 - 5322. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Oestreich, H. Yoon, R. Ahmed, and J. M. Boss NFATc1 Regulates PD-1 Expression upon T Cell Activation J. Immunol., October 1, 2008; 181(7): 4832 - 4839. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Deppong, J. M. Degnan, T. L. Murphy, K. M. Murphy, and J. M. Green B and T Lymphocyte Attenuator Regulates T Cell Survival in the Lung J. Immunol., September 1, 2008; 181(5): 2973 - 2979. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Steinberg, O. Turovskaya, R. B. Shaikh, G. Kim, D. F. McCole, K. Pfeffer, K. M. Murphy, C. F. Ware, and M. Kronenberg A crucial role for HVEM and BTLA in preventing intestinal inflammation J. Exp. Med., June 9, 2008; 205(6): 1463 - 1476. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tao, L. Wang, K. M. Murphy, C. C. Fraser, and W. W. Hancock Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells J. Immunol., May 15, 2008; 180(10): 6649 - 6655. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Nelson, M. D. Fremont, J. R. Sedy, P. S. Norris, C. F. Ware, K. M. Murphy, and D. H. Fremont Structural Determinants of Herpesvirus Entry Mediator Recognition by Murine B and T Lymphocyte Attenuator J. Immunol., January 15, 2008; 180(2): 940 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. De Trez, K. Schneider, K. Potter, N. Droin, J. Fulton, P. S. Norris, S.-w. Ha, Y.-X. Fu, T. Murphy, K. M. Murphy, et al. The Inhibitory HVEM-BTLA Pathway Counter Regulates Lymphotoxin Receptor Signaling to Achieve Homeostasis of Dendritic Cells J. Immunol., January 1, 2008; 180(1): 238 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lepenies, K. Pfeffer, M. A. Hurchla, T. L. Murphy, K. M. Murphy, J. Oetzel, B. Fleischer, and T. Jacobs Ligation of B and T Lymphocyte Attenuator Prevents the Genesis of Experimental Cerebral Malaria J. Immunol., September 15, 2007; 179(6): 4093 - 4100. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okazaki and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int. Immunol., July 2, 2007; (2007) dxm057v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Hurchla, J. R. Sedy, and K. M. Murphy Unexpected Role of B and T Lymphocyte Attenuator in Sustaining Cell Survival during Chronic Allostimulation J. Immunol., May 15, 2007; 178(10): 6073 - 6082. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, A. S. Flies, D. B. Flies, G. Zhu, S. Anand, S. J. Flies, H. Xu, R. A. Anders, W. W. Hancock, L. Chen, et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease Blood, May 1, 2007; 109(9): 4097 - 4104. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Chemnitz, A. R. Lanfranco, I. Braunstein, and J. L. Riley B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs. J. Immunol., June 1, 2006; 176(11): 6603 - 6614. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |